The DOI matches its Crossref record.
FDG PET in the diagnosis of hilar cholangiocarcinoma
Abstract
Resectional surgery offers a curative intent and a survival benefit for patients with hilar cholangiocarcinoma, but is associated with high morbidity. Since morphological imaging cannot solve differential diagnosis preoperatively, in order to exclude patients inappropriate to this aggressive surgery, we evaluated the impact of functional imaging using fluorodeoxyglucose positron emission tomography (FDG PET) in the detection of cholangiocarcinoma and its usefulness in the differentiation from benign Klatskin tumour-mimicking lesions. Fifteen consecutive patients aged 47-78 years underwent standardized whole-body FDG PET with attenuation correction before potentially curative surgery using a conventional full-ring PET scanner with an axial field-of-view of 16.2 cm. FDG PET was evaluated visually and semiquantitatively using tumour-to-background ratios (T/B) ratios. All lesions were evaluated histopathologically. FDG PET presumed to be indicative for carcinoma was positive in 12 of 15 patients, true positive in 10 (T/B ratio, 3.2+/-1.9) and false positive in two of them (T/B ratios, 2.1 and 2.8) with Klatskin tumour-mimicking lesions. While all true positive PET results were seen in the tubular type of cholangiocarcinoma with a high amount of tumour cells and only low production of mucus, a false negative FDG PET in three patients was observed in mucinous adenocarcinoma. Additionally, FDG PET detected locoregional lymph nodes in two patients and distant metastases in a further three patients. Due to false positive results FDG PET does not allow the differentiation of benign from malignant lesions, and FDG PET should be avoided in patients with mucinous cholangiocarcinoma. However, FDG PET may have significant influence on the treatment strategy in as much as 20% of the patients, since it may detect distant metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Khan, S. A., Thomas, H. C., Davidson, B. R., & Taylor-Robinson, S. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67530-7 · Cited by 1,042
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment†
Blechacz, B., & Gores, G. J. (2008) · Hepatology · doi:10.1002/hep.22310 · Cited by 681
Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma
Anderson, C. D., Rice, M. H., Pinson, C. W., Chapman, W. C., Chari, R. S., & Delbeke, D. (2004) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2003.10.003 · Cited by 377
Petrowsky, H., Wildbrett, P., Husarik, D. B., Hany, T. F., Tam, S., Jochum, W., & Clavien, P.-A. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.03.009 · Cited by 305
Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma
Esnaola, N. F., Meyer, J. E., Karachristos, A., Maranki, J. L., Camp, E. R., & Denlinger, C. S. (2016) · Cancer · doi:10.1002/cncr.29692 · Cited by 296
Metadata
- Authors
- FRITSCHER-RAVENS, A., BOHUSLAVIZKI, K. H., BROERING, D. C., JENICKE, L., SCHÄFER, H., BUCHERT, R., ROGIERS, X., & CLAUSEN, M.
- Venue
- Nuclear Medicine Communications
- Published
- 2001-12
- Volume
- 22
- Issue
- 12
- Pages
- 1277-1285
- ISSN
- 0143-3636 (ISSN-L)
- OpenAlex
- W2333341930
- Cited by
- 160
- References
- 0
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDG PET in the diagnosis of hilar cholangiocarcinoma. https://app.cochat.ai/papers/10.1097/00006231-200112000-00002
- The paper
- FRITSCHER-RAVENS, A., BOHUSLAVIZKI, K. H., BROERING, D. C., JENICKE, L., SCHÄFER, H., BUCHERT, R., ROGIERS, X., & CLAUSEN, M. (2001). FDG PET in the diagnosis of hilar cholangiocarcinoma. Nuclear Medicine Communications. https://doi.org/10.1097/00006231-200112000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.